Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
J Neurosurg ; 114(5): 1471-8, 2011 May.
Article in English | MEDLINE | ID: mdl-21214327

ABSTRACT

OBJECT: The normalization of increased intracranial pressure (ICP) in patients with severe traumatic brain injury (TBI) is assumed to limit secondary brain injury and improve outcome. Despite evidence-based recommendations for monitoring and treatment of elevated ICP, there are few studies that show an association between response to ICP-directed therapeutic regimens and adjusted mortality rate. This study utilizes a large prospective database to examine the effect of response to ICP-lowering therapy on risk of death within the first 2 weeks of injury in patients who sustained TBI and are older than 16 years. METHODS: The current study is based on 1426 patients with severe TBI (Glasgow Coma Scale [GCS] score < 9) of whom 388 were treated for elevated ICP (> 25 mm Hg) between 2000 and 2008 at 22 trauma centers enrolled in a New York State quality improvement program. This prospectively collected database also contains information including age, admission GCS score, pupillary status, CT scanning parameters, and hypotension, which are all known early prognostic indicators of death. Treatment of elevated ICP consisted of administration of mannitol, hypertonic saline, barbiturates, and/or drainage of CSF or decompressive craniectomy. The factors predicting ICP response to treatment and predicting death at 2 weeks were evaluated using logistic regression analyses. RESULTS: Increasing age and fewer hours of elevated ICP on Day 1 were found to be significant predictors (p = 0.001 and 0.0003, respectively) of a positive response to treatment. Response to ICP-lowering therapy (p = 0.03), younger age (p < 0.0001), fewer hours of elevated ICP (p < 0.0001), and absence of arterial hypotension on Day 1 (p = 0.001) significantly predicted reduced risk of death. CONCLUSIONS: Patients who responded to ICP-lowering treatment had a 64% lower risk of death at 2 weeks than those who did not respond after adjusting for factors that independently predict risk of death.


Subject(s)
Brain Injuries/physiopathology , Brain Injuries/therapy , Intracranial Hypertension/physiopathology , Intracranial Hypertension/therapy , Intracranial Pressure/physiology , Adolescent , Adult , Aged , Aged, 80 and over , Barbiturates/administration & dosage , Brain Injuries/mortality , Craniotomy , Decompression, Surgical , Female , Glasgow Coma Scale , Humans , Intracranial Hypertension/mortality , Intracranial Pressure/drug effects , Logistic Models , Male , Mannitol/administration & dosage , Middle Aged , Multivariate Analysis , New York , Prognosis , Retrospective Studies , Risk , Saline Solution, Hypertonic/administration & dosage , Spinal Puncture , Survival Rate , Tomography, X-Ray Computed , Trauma Centers , Young Adult
2.
Crit Care Med ; 37(4): 1433-41, 2009 Apr.
Article in English | MEDLINE | ID: mdl-19242317

ABSTRACT

OBJECTIVE: To evaluate potential side effects of continuous hypertonic 3% saline (CHS) as maintenance fluid in patients with brain injury. METHODS: Retrospective chart analysis of prospectively collected data. PATIENTS: Patients admitted to the neurosurgical intensive care unit for >4 days with traumatic brain injury, stroke, or subarachnoid hemorrhage with a Glasgow Coma Scale <9 and elevated intracranial pressure (ICP) or at risk of developing elevated ICP were included. Based on physician preference, one group was treated with 3% CHS at a rate of 1.5 mL/kg/bw as maintenance fluid. The other group received 0.9% normal saline (NS). Two percent saline was used in the CHS group to wean patients off 3% CHS or when sodium was above 155. Data on serum sodium, blood urea nitrogen, creatinine, ICP, infection rate, length of stay, rates of deep vein thrombosis, and pulmonary emboli and dural thrombosis were collected prospectively. RESULTS: One hundred seven patients in the CHS group and 80 in the NS group met the inclusion criteria. The incidence of moderate hypernatremia (Na >155 mmol/L) and severe hypernatremia (Na >160 mmol/L) was significantly higher in the CHS therapy group than in the NS group. No significant relationship between CHS infusion and renal dysfunction was found. Moderate and severe hypernatremia was associated with a higher risk of elevated blood urea nitrogen and creatinine levels. Acute renal failure was not seen in these patients. A total of 53.3% in the CHS group and in 16.3% in the NS group (p < 0.0001) had raised ICP (>25 mm Hg), consistent with the physicians decision to use CHS in patients with elevated ICP. CONCLUSIONS: CHS therapy was not associated with an increased rate of infection, deep vein thrombosis, or renal failure. However, there was a significant risk of developing hypernatremia. We conclude that CHS administration in patients with severe injuries is safe as long as sodium levels are carefully monitored.


Subject(s)
Brain Injuries/therapy , Saline Solution, Hypertonic/adverse effects , Stroke/therapy , Subarachnoid Hemorrhage/therapy , Brain Injuries/physiopathology , Critical Illness , Female , Humans , Kidney/physiopathology , Male , Middle Aged , Retrospective Studies , Saline Solution, Hypertonic/administration & dosage , Saline Solution, Hypertonic/therapeutic use , Stroke/physiopathology , Subarachnoid Hemorrhage/physiopathology
SELECTION OF CITATIONS
SEARCH DETAIL
...